The current weakness (shares are only 5.2$ now) is a buying opportunity imo
The latest financing was at around 6.3, with all very long term focused investors who are not invested for a potential of just 100% No, they want the exposure to the FULL upside of the Diabetes compound AND Oncoprex
Many months without news for this company, but yesterday there was big news:
FDA grants Fast Track to its Reqorsa + Keytruda combo
and there was already the FTD for Reqorsa + Tagrisso
...
huge volume and maybe the start of a run, back to the 7$ of last year and maybe even higher last financing was at 6.5$ Keytruda: MRK Tagrisso: AZN ONC 002 with a Genentech/Roche Tarceva